Summarized by Masters of Longevity from MedTech Dive.
Johnson & Johnson led funding so Francis can pursue FDA premarket approval.
Key Takeaways
- Johnson & Johnson is funding Vanquish development via its venture arm.
- A 235‑patient trial showed 75% benign biopsies at six months.
- Functional declines were initial but generally improved toward baseline.
